Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a significant decline in short interest in the month of August. As of August 15th, there was short interest totalling 30,700 shares, a decline of 89.7% from the July 31st total of 298,700 shares. Based on an average trading volume of 324,800 shares, the days-to-cover ratio is currently 0.1 days.

Astellas Pharma Price Performance

OTCMKTS ALPMY traded down $0.24 on Tuesday, reaching $12.34. The company’s stock had a trading volume of 36,149 shares, compared to its average volume of 279,271. The firm has a market cap of $22.33 billion, a PE ratio of 176.29 and a beta of 0.38. The business has a 50-day moving average price of $10.74 and a 200 day moving average price of $10.44. Astellas Pharma has a 52 week low of $9.15 and a 52 week high of $15.63. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.31.

Astellas Pharma (OTCMKTS:ALPMY) last posted its earnings results on Thursday, August 1st. The company reported $0.24 earnings per share for the quarter. The business had revenue of $3.03 billion for the quarter. Astellas Pharma had a net margin of 1.17% and a return on equity of 7.75%. Sell-side analysts expect that Astellas Pharma will post 0.51 EPS for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.